Your browser doesn't support javascript.
loading
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.
Brown, J William L; Cunniffe, Nick G; Prados, Ferran; Kanber, Baris; Jones, Joanne L; Needham, Edward; Georgieva, Zoya; Rog, David; Pearson, Owen R; Overell, James; MacManus, David; Samson, Rebecca S; Stutters, Jonathan; Ffrench-Constant, Charles; Gandini Wheeler-Kingshott, Claudia A M; Moran, Carla; Flynn, Paul D; Michell, Andrew W; Franklin, Robin J M; Chandran, Siddharthan; Altmann, Daniel R; Chard, Declan T; Connick, Peter; Coles, Alasdair J.
Affiliation
  • Brown JWL; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK; NMR Research Unit, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, University College London, London, UK; Clinical Outcomes Research Unit, University of Melbourne, Melbourne, VIC, Australia
  • Cunniffe NG; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. Electronic address: ngc26@cam.ac.uk.
  • Prados F; NMR Research Unit, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, University College London, London, UK; Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, UK; e-Health Center, Universitat
  • Kanber B; NMR Research Unit, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, University College London, London, UK; Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, UK; National Institute for Healt
  • Jones JL; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
  • Needham E; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
  • Georgieva Z; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
  • Rog D; Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK.
  • Pearson OR; Department of Neurology, Swansea Bay University Health Board, Swansea, UK.
  • Overell J; Product Development Neuroscience, F Hoffmann-La Roche, Basel, Switzerland; Institute of Neurological Sciences, University of Glasgow, Glasgow, UK.
  • MacManus D; NMR Research Unit, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
  • Samson RS; NMR Research Unit, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
  • Stutters J; NMR Research Unit, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
  • Ffrench-Constant C; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
  • Gandini Wheeler-Kingshott CAM; NMR Research Unit, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, University College London, London, UK; Brain Connectivity Centre, IRCCS Mondino Foundation, Pavia, Italy; Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.
  • Moran C; Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • Flynn PD; Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.
  • Michell AW; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
  • Franklin RJM; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
  • Chandran S; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.
  • Altmann DR; Medical Statistics Department, London School of Hygiene & Tropical Medicine, London, UK.
  • Chard DT; NMR Research Unit, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, University College London, London, UK; National Institute for Health Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust and University College London, London
  • Connick P; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
  • Coles AJ; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Lancet Neurol ; 20(9): 709-720, 2021 09.
Article in En | MEDLINE | ID: mdl-34418398
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Outcome Assessment, Health Care / Multiple Sclerosis, Relapsing-Remitting / Retinoid X Receptors / Drug-Related Side Effects and Adverse Reactions / Remyelination / Bexarotene Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Lancet Neurol Journal subject: NEUROLOGIA Year: 2021 Type: Article Affiliation country: Australia
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Outcome Assessment, Health Care / Multiple Sclerosis, Relapsing-Remitting / Retinoid X Receptors / Drug-Related Side Effects and Adverse Reactions / Remyelination / Bexarotene Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Lancet Neurol Journal subject: NEUROLOGIA Year: 2021 Type: Article Affiliation country: Australia